rs1799931

This is a variant in the NAT2 gene that changes a glycine to an glutamate.

ClinVar annotation

Drug Response
1 submitter3 publications

Slow acetylator due to N-acetyltransferase enzyme variant

View on ClinVar →

Research that mentions this SNP (6)

Relevance of NAT2 genotype to anti‐tuberculosis drug‐induced hepatotoxicity in a Chinese Han population
ReviewN=60,888Lihuan Lu et al.(2019)· The Journal of Gene Medicine

Systematic review of worldwide genetic diversity of the NAT2 gene across 60,888 individuals from 122 populations in 51 countries. Analyzed eight NAT2 polymorphisms (rs1801279, rs1041983, rs1801280, rs1799929, rs1799930, rs1208, rs1799931, rs1495741) to characterize acetylation phenotypes globally. Slow phenotype most common worldwide (frequency 0.44), especially in African, European, and Middle Eastern populations (0.48-0.79), while rapid phenotype predominates in East Asians and Native Americans (0.25-0.53). Compiled data from 160 publications including 115 case-control studies to map NAT2 diversity patterns associated with metabolism of drugs and heterocyclic aromatic amines.

Traits studied:Allergy and asthmaBladder cancerBreast cancerColorectal cancerDrug metabolism (sulfonamides, hydralazine)Heterocyclic aromatic amine metabolismLupus erythematosusMale infertilityNAT2 acetylation phenotypeProstate cancer
Determination of NAT2 acetylation status in the Greenlandic population
AssociationN=1,556Frank Geller et al.(2016)· Archives of Toxicology

This study determined NAT2 (N-acetyltransferase 2) acetylation status in 1,556 Greenlandic individuals using SNP panels and genotype imputation. The fraction of slow acetylators was 17.5% overall but varied significantly by Inuit ancestry (12.2% with >70% Inuit ancestry vs 25.6% with <50% Inuit ancestry). Different SNP panels showed high concordance (2-SNP and 4-SNP panels achieved 100% agreement with the 7-SNP reference panel), demonstrating reliable NAT2 status assessment. These findings support pharmacogenetics-based isoniazid dosing for tuberculosis treatment in Greenland.

Traits studied:Drug metabolism pharmacogenotypeIsoniazid metabolismNAT2 acetylation status
Variation in PAH‐related DNA adduct levels among non‐smokers: The role of multiple genetic polymorphisms and nucleotide excision repair phenotype
AssociationN=111Arash Etemadi et al.(2013)· International Journal of Cancer

This study examined PAH-related DNA adduct levels in 111 female never-smokers from Iran, evaluating 21 SNPs in 14 xenobiotic metabolism genes and 12 SNPs in 8 DNA repair genes. DNA adduct levels were significantly lower with NAT2 slow alleles (β=-0.24, p=0.01) and ERCC5 non-risk genotype (β=0.16, p=0.04), but higher with MPO risk alleles (β=0.21, p=0.01). The combination of phase I genes and measured NER capacity explained 17% more variation in adduct levels than environmental exposure alone (r²=0.24 vs 0.07), demonstrating the importance of genetic polymorphisms in PAH metabolism and DNA repair capacity.

Traits studied:Nucleotide excision repair (NER) capacityPAH-related DNA adduct levels
Clinical significance of SOD2 and GSTP1 gene polymorphisms in Chinese patients with gastric cancer
AssociationN=324Zhi Xu et al.(2012)· Cancer

Case-control study of 324 Japanese male workers examining genetic polymorphisms in xenobiotic-metabolizing enzymes (CYP2E1, NAT2, GSTM1, GSTT1, GSTP1, ALDH2, SOD2) and their association with multiple chemical sensitivity (MCS). SOD2 Val16Ala polymorphism (rs4880) showed significant association with high chemical sensitivity, with adjusted OR of 4.30 (95% CI 1.23-15.03) for Ala/Ala and Val/Ala genotypes versus Val/Val, and adjusted OR of 4.53 (95% CI 1.52-13.51) in additive genetic model analysis.

Traits studied:Chemical sensitivityMultiple chemical sensitivity
Smoking, the xenobiotic pathway, and clubfoot
AssociationN=1,776Sommer A. et al.(2011)· Birth Defects Research Part A: Clinical and Molecular Teratology

This family-based association study examined genetic variation in xenobiotic metabolism genes and clubfoot risk. In 1,776 individuals from 619 families, rs1048943/CYP1A1 showed significant altered transmission (p=0.003), and CYP1A2 variants demonstrated both maternal (rs11854147, p=0.03, RR=1.24) and fetal (rs2470890, p=0.01, RR=1.33) genotypic effects. A significant gene interaction was detected between rs105740/EPHX1 and rs1799929/NAT2 (p=0.007). The authors conclude that xenobiotic metabolism genes may contribute to clubfoot susceptibility, particularly in the context of maternal smoking exposure.

Traits studied:ClubfootIdiopathic talipes equinovarus
Modulation of urinary polycyclic aromatic hydrocarbon metabolites by enzyme polymorphisms in workers of the German Human Bitumen Study
AssociationN=314Hans-Peter Rihs et al.(2011)· Archives of Toxicology

Study of 314 German workers (218 bitumen-exposed, 96 non-exposed controls) examining how 18 SNPs in metabolizing enzyme genes modulate urinary PAH metabolites (1-OHP and OHPHE). The CYP1A1 3801T>C CC variant showed 58% higher OHPHE (P=0.051), GSTM1*1 carriers had 11% lower OHPHE (P=0.046), and NAT2*803GG showed 15-16% decrease in OHPHE (P=0.042). No SNPs reached significance for 1-OHP.

Traits studied:1-hydroxypyrene (1-OHP) urinary levelsBitumen occupational exposure responseHydroxyphenanthrene (OHPHE) urinary levelsPolycyclic aromatic hydrocarbon metabolism

About NAT2

This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second polymorphic arylamine N-acetyltransferase gene (NAT1), is located near this gene (NAT2). [provided by RefSeq, Sep 2019]

View all NAT2 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…